Saturday, February 12, 2022, 8:30 AM – 4:00 PM Eastern Time

Recent Advances and Real-World Implications in Medical Oncology: A Daylong Multitumor Educational Symposium in Partnership with the North Carolina Oncology Association and the South Carolina Oncology Society

A CME-MOC/NCPD Accredited Event

Location
The Westin Charlotte
601 South College Street
Charlotte, NC 28202
Hotel Phone: (704) 375-2600

Event Schedule
8:30 AM – 4:00 PM
Breakfast and lunch buffet to be provided

Meeting Room
Grand Ballroom A-C (Second Floor)

There is no registration fee for this event. However, preregistration is advised as seating is limited and you must be registered to attend the NCOA/SCOS 2022 Joint Conference.  
 
Faculty Presenting Virtually

Chronic Lymphocytic Leukemia and Lymphomas

Ian W Flinn, MD, PhD
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Ann S LaCasce, MD, MMSc
Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
Associate Professor of Medicine, Harvard Medical School
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Multiple Myeloma

Natalie S Callander, MD
Professor of Medicine
Director, Myeloma Clinical Program
Interim Director, Bone Marrow Transplant Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

S Vincent Rajkumar, MD
Edward W and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Genitourinary Cancers

Robert Dreicer, MD, MS
Section Head, Medical Oncology
Deputy Director, University of Virginia Comprehensive Cancer Center
Associate Director for Clinical Research
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia


Breast Cancer

Sara M Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F Smith Center for Women's Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Gastrointestinal Cancers

Howard S Hochster, MD
CINJ Associate Director, Clinical Research
Director Clinical Oncology Research
Rutgers Cancer Institute
New Brunswick, New Jersey

Wells A Messersmith, MD
Chief Medical Officer, Cancer Center
Associate Director of Clinical Services
University of Colorado Cancer Center
Aurora, Colorado

Lung Cancer

Ramaswamy Govindan, MD
Professor of Medicine
Director, Section of Oncology
Anheuser-Busch Endowed Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Melissa Johnson, MD
Director, Lung Cancer Research Program
Associate Director of Drug Development for the Drug
Development Unit in Nashville
Sarah Cannon Research Institute
Nashville, Tennessee

Additional faculty to be announced.

Moderator Hosting Virtually
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Epizyme Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Novartis, Seagen Inc, and Taiho Oncology Inc.

Event Schedule
8:30 AM – 4:00 PM
Breakfast and lunch buffet to be provided

Opening Remarks | 8:30 AM – 8:35 AM

Chronic Lymphocytic Leukemia (CLL) and Lymphomas | 8:35 AM – 9:40 AM

  • Pivotal data sets with BTK inhibitor-based therapy for treatment-naïve CLL
  • Implications for therapeutic decision-making of results from the Phase III ELEVATE-RR study of acalabrutinib versus ibrutinib for previously treated high-risk CLL
  • Results from the Phase III ALPINE and SEQUOIA trials evaluating zanubrutinib for CLL
  • Key data sets informing the optimal utilization of venetoclax for newly diagnosed CLL
  • Current role and optimal platforms for minimal residual disease assessment in patients with CLL
  • Unique mechanism of action of the PI3K-delta inhibitor umbralisib; efficacy and safety in combination with the anti-CD20 antibody ublituximab in the Phase III UNITY-CLL study
  • Efficacy and safety of pirtobrutinib in the Phase I/II BRUIN study; ongoing investigation and potential clinical role
  • Results from the Phase III GLOW trial of first-line ibrutinib/venetoclax versus chlorambucil/obinutuzumab
  • CD19-directed chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory (R/R) CLL
  • Integration of obinutuzumab into current algorithms for treatment-naïve and R/R follicular lymphoma (FL)
  • Lenalidomide/rituximab in the management of newly diagnosed and R/R FL
  • Key findings from the Phase III CHRONOS-3 trial of copanlisib in combination with rituximab for patients with R/R FL
  • Available data from the Phase IIb UNITY-NHL trial evaluating umbralisib for patients with R/R FL; FDA approval of umbralisib
  • Results from the Phase II CITADEL-203 study evaluating the next-generation PI3K inhibitor parsaclisib
  • Optimal integration of tazemetostat into the management of previously treated FL with and without EZH2 mutations
  • Available data with and FDA approval of axicabtagene ciloleucel (axi-cel) for patients with R/R FL
  • Potential clinical role of tisagenlecleucel (tis-cel) in FL treatment
  • Early-phase data and potential clinical role of investigational bispecific antibodies (eg, mosunetuzumab, glofitamab, epcoritamab) for R/R FL
  • Emerging results from the Phase III POLARIX study comparing polatuzumab vedotin in combination with chemotherapy to R-CHOP for previously untreated diffuse large B-cell lymphoma (DLBCL); implications for clinical practice
  • Published research findings with polatuzumab vedotin in combination with bendamustine/rituximab for R/R DLBCL
  • Available data with and recent FDA approval of loncastuximab tesirine
  • Key data leading to the FDA approval of tafasitamab/lenalidomide for R/R DLBCL
  • Long-term data with axi-cel, tis-cel and lisocabtagene maraleucel (liso-cel) for R/R DLBCL; recent FDA approval of liso-cel and optimal integration into patient care
  • Phase III data of CAR T-cell therapy as second-line treatment of DLBCL
  • Research database supporting the FDA approvals of ibrutinib, acalabrutinib and zanubrutinib in R/R mantle cell lymphoma (MCL); key factors in the choice of Bruton tyrosine kinase (BTK) inhibitor and practical use of these agents
  • Activity and safety data with and ongoing Phase III investigations of novel agents (eg, lenalidomide, BTK inhibitors) for previously untreated MCL
  • Venetoclax alone or combined with other agents (eg, BTK inhibitors) for patients with MCL
  • FDA approval of brexucabtagene autoleucel and optimal integration into MCL treatment algorithms
  • Efficacy and safety observed with pirtobrutinib in patients with MCL in the Phase I/II BRUIN trial
  • Available data with parsaclisib for patients with R/R MCL in the Phase II CITADEL-205 study
  • Long-term follow-up from the Phase III ECHELON-1 trial of first-line brentuximab vedotin (BV) and AVD
  • Early findings with BV combined with chemotherapy for localized, unfavorable-risk Hodgkin lymphoma
  • Current role of BV for older patients with newly diagnosed Hodgkin lymphoma
  • Potential role of BV alone or in combination with immune checkpoint inhibition as a bridge to transplant
  • Key outcomes from the Phase III KEYNOTE-204 trial of pembrolizumab versus BV for patients with R/R Hodgkin lymphoma; implications for clinical practice

Multiple Myeloma | 9:40 AM – 10:45 AM

  • Current utility of carfilzomib as a component of up-front therapy
  • Updated data on lenalidomide/bortezomib/dexamethasone with daratumumab for transplant-eligible, newly diagnosed MM; recent NCCN guideline inclusion and current nonresearch role
  • Correlation between minimal residual disease (MRD) negativity and long-term outcomes for patients with newly diagnosed MM undergoing active treatment
  • Current role of MRD assessment to inform MM decision-making and optimal platforms for MRD assessment
  • Optimal approach to maintenance therapy for transplant-eligible patients, including those who have received daratumumab-based induction therapy
  • Daratumumab-containing front-line regimens for patients ineligible for transplant
  • Available data with and current indications, if any, for ixazomib in the induction and maintenance settings
  • Ongoing clinical trials evaluating novel induction approaches for transplant-eligible patients
  • Recent FDA approval of idecabtagene vicleucel and updated results from the pivotal Phase II KarMMa trial evaluating this agent for patients with relapsed/refractory (R/R) MM
  • Available data from the CARTITUDE-1 and CARTITUDE-2 studies of ciltacabtagene autoleucel for pretreated MM; potential clinical role
  • Incidence, severity and management of class-effect toxicities observed with B-cell maturation antigen (BCMA)-targeted CAR (chimeric antigen receptor) T-cell therapies
  • Early data with and ongoing research efforts evaluating other CAR T-cell platforms/strategies for MM
  • Mechanism of action of isatuximab; structural and pharmacologic similarities and differences between isatuximab and daratumumab and implications, if any, for activity and tolerability
  • Published Phase III research experience with isatuximab for R/R MM (eg, ICARIA-MM, IKEMA trials)
  • Results from the Phase III BOSTON trial evaluating selinexor in combination with bortezomib/dexamethasone for patients with R/R MM; FDA approval of and patient selection for this regimen
  • Ongoing studies of selinexor in combination with other agents and in earlier lines of therapy
  • Efficacy and safety results from the Phase II DREAMM-2 study leading to the FDA approval of belantamab mafodotin monotherapy for patients with R/R MM; incorporation into routine practice
  • Monitoring for and management of ocular and other toxicities with belantamab mafodotin
  • Available data with and ongoing evaluation of belantamab mafodotin in combination with other systemic therapies
  • Available safety and efficacy data with and ongoing evaluation of BCMA-directed bispecific antibodies (eg, teclistamab, elranatamab)
  • Phase III CANOVA trial evaluating venetoclax/dexamethasone versus pomalidomide/dexamethasone for patients with R/R MM with t(11;14); other ongoing studies assessing venetoclax-based combinations
  • Activity and safety observed with each of the cereblon E3 ligase modulators iberdomide and CC-92480 in patients with heavily pretreated MM
  • Rationale for targeting GPRC5D and FcRH5 in patients with MM
  • Published research findings with and ongoing efforts evaluating novel bispecific antibodies talquetamab and cevostamab
  • Other promising novel agents and strategies under investigation in patients with MM

Genitourinary Cancers | 10:45 AM – 11:50 AM

  • Key efficacy outcomes with enzalutamide, apalutamide and darolutamide in nonmetastatic castration-resistant prostate cancer; implications of differential toxicity profiles for therapeutic selection
  • Long-term outcomes with docetaxel, abiraterone, enzalutamide and apalutamide in combination with androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC); clinical and biologic factors guiding selection among these agents
  • PEACE-1 trial: Docetaxel with or without abiraterone with or without local radiation therapy for men with de novo mHSPC; potential implications for clinical practice
  • Efficacy and safety of approved PARP inhibitors (olaparib and rucaparib) in men with metastatic castration-resistant prostate cancer (mCRPC); optimal integration of these agents into current management algorithms
  • Results of the Phase III PROpel trial comparing olaparib/abiraterone versus abiraterone alone as first-line therapy for patients with mCRPC with or without HRR gene mutations
  • Patient selection for and optimal integration of radium-223 into current mCRPC treatment algorithms
  • Findings from the Phase III VISION study evaluating 177Lu-PSMA-617 for progressive PSMA-positive mCRPC; potential role in current management algorithms
  • Findings from the Phase III KEYNOTE-564 study of adjuvant pembrolizumab for high-risk clear-cell renal cell carcinoma (RCC); FDA approval and patient selection
  • Use of nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib for treatment-naïve metastatic RCC (mRCC)
  • FDA approval for lenvatinib/pembrolizumab as first-line therapy for mRCC
  • Results of the Phase III CheckMate 9ER trial of nivolumab plus cabozantinib for previously untreated mRCC; FDA approval and optimal integration into current first-line treatment algorithms
  • FDA approval and optimal clinical role of tivozanib for patients with mRCC
  • Activity of, FDA approval for and ongoing evaluation of belzutifan in patients with von Hippel-Lindau disease-associated RCC
  • Selection of appropriate patients with high-risk, non-muscle-invasive bladder cancer for pembrolizumab therapy
  • Results of the Phase III CheckMate 274 trial comparing nivolumab to placebo after surgery for patients with high-risk muscle-invasive bladder cancer; recent FDA approval and optimal integration into practice
  • Current clinical role of atezolizumab and pembrolizumab as first-line treatment for metastatic urothelial bladder cancer (mUBC); importance of chemotherapy eligibility and PD-L1 status in patient selection for this strategy
  • Activity of enfortumab vedotin in progressive mUBC; FDA-approved indication and optimal integration into current treatment paradigms
  • Efficacy and potential clinical role of enfortumab vedotin/pembrolizumab for patients with previously untreated mUBC
  • Clinical role of erdafitinib for patients with mUBC and FGFR3 or FGFR2 genetic alterations
  • Findings from the Phase II TROPHY U-01 trial leading to the recent FDA approval of sacituzumab govitecan for patients with progressive mUBC; optimal integration into current clinical management
  • FDA breakthrough therapy designation for disitamab vedotin for second-line, HER2-positive bladder cancer

LUNCH BREAK | 11:50 AM – 12:30 PM

Breast Cancer | 12:30 PM – 1:35 PM

  • Feasibility of chemotherapy de-escalation with dual HER2 blockade in patients with localized disease
  • Adjuvant T-DM1 for patients with residual disease after neoadjuvant therapy
  • Neratinib as extended adjuvant therapy; improvement in rates of CNS recurrence after long-term follow-up in the Phase III ExteNET study
  • Optimizing the use of postadjuvant neratinib; available data with and rationale for a dose- escalation strategy
  • Ongoing clinical trials (eg, DESTINY-Breast05, CompassHER2 RD, MARGOT) investigating novel HER2-targeted strategies in HER2-positive, localized breast cancer
  • Published data from the pivotal HER2CLIMB, DESTINY-Breast01 and NALA studies of tucatinib/trastuzumab/capecitabine, trastuzumab deruxtecan (T-DXd) and neratinib/capecitabine, respectively, for HER2-positive metastatic breast cancer (mBC)
  • Integration of tucatinib/trastuzumab/capecitabine, T-DXd, neratinib/capecitabine and margetuximab/chemotherapy into practice for patients with and without brain metastases
  • Key data from the Phase III DESTINY-Breast03 trial evaluating T-DXd versus T-DM1 for previously treated HER2-positive mBC
  • Early data with and ongoing evaluation of T-DXd in patients with HER2-low breast cancer
  • Ongoing clinical studies (eg, HER2CLIMB-02, DESTINY-Breast07) evaluating novel HER2-targeted combination strategies for HER2-positive mBC
  • Major findings from the Phase III RxPONDER trial evaluating chemotherapy in patients with ER-positive, HER2-negative localized breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score® ≤25
  • Other recent data informing the use of genomic assays (eg, ADAPT) to guide neoadjuvant and adjuvant treatment decision-making
  • Key outcomes observed with abemaciclib added to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer in the Phase III monarchE trial; FDA approval and current role of adjuvant abemaciclib
  • Other ongoing studies evaluating CDK4/6 inhibitors as neoadjuvant or adjuvant therapy
  • Long-term follow-up data with CDK4/6 inhibitors in patients with ER-positive mBC
  • Incidence, monitoring and management of commonly occurring class- and agent-specific toxicities associated with CDK4/6 inhibition
  • Major research findings with alpelisib/fulvestrant in patients with ER-positive mBC and a PIK3CA mutation
  • Optimal prevention and management strategies for alpelisib-related toxicities
  • Mechanism of action of, available findings with and ongoing investigation of oral selective estrogen receptor degraders
  • Other novel agents and strategies under investigation for patients with ER-positive mBC (eg, patritumab deruxtecan, capivasertib, sacituzumab govitecan)
  • Key outcomes of the Phase III OlympiA trial assessing adjuvant olaparib for patients with germline BRCA1/2 mutations and high-risk, HER2-negative breast cancer; current and potential role of adjuvant olaparib
  • Available data from the Phase III KEYNOTE-522 study of neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk, localized triple-negative breast cancer (TNBC)
  • Other ongoing studies evaluating PARP inhibitors or immune checkpoint inhibitors as a component of neoadjuvant or adjuvant therapy
  • Phase III data sets evaluating anti-PD-1/PD-L1 antibodies with chemotherapy for patients with previously untreated PD-L1-positive metastatic TNBC (mTNBC)
  • Clinical implications of the recent voluntary withdrawal of the first-line indication for atezolizumab/nab-paclitaxel for mTNBC
  • Key findings guiding the optimal use of PARP inhibitors for patients with mBC
  • Available data from the Phase III ASCENT trial comparing sacituzumab govitecan to physician’s choice chemotherapy for relapsed/refractory TNBC; FDA approval and optimal integration into clinical practice
  • Other novel agents under investigation for patients with mTNBC (eg, T-DXd, ladiratuzumab vedotin, datopotamab deruxtecan)

Gastrointestinal Cancers | 1:35 PM – 2:40 PM

  • Biologic rationale for and potential clinical utility of the assessment of MRD in patients with colorectal cancer (CRC); available testing methodologies
  • Available data linking tumor sidedness to response to specific therapies for metastatic CRC (mCRC)
  • Encorafenib/cetuximab for mCRC with a BRAF V600E mutation
  • Appropriate integration of encorafenib/cetuximab into therapy for patients with mCRC with BRAF V600E mutations; available results with and ongoing evaluation of earlier use of BRAF-targeted therapy
  • Immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient mCRC
  • Regorafenib and TAS-102 in the treatment of multiregimen-relapsed mCRC
  • Available data with and potential role of TAS-102 in combination with other systemic agents for mCRC or earlier disease stages; NCCN guideline inclusion of TAS-102/bevacizumab
  • Updated results from the DESTINY-CRC01 study of T-DXd for HER2-expressing mCRC
  • Early results with and ongoing evaluation of the KRAS G12C inhibitor sotorasib for mCRC with a KRAS G12C mutation
  • Phase III data supporting the use of first-line chemoimmunotherapy regimens for advanced gastric, gastroesophageal junction (GEJ) and esophageal cancer
  • Available data from the Phase III CheckMate 577 study of adjuvant nivolumab for resected esophageal or GEJ cancer
  • Optimal placement of ramucirumab in current clinical algorithms for metastatic gastric/GEJ cancer; ongoing investigation of ramucirumab-containing combination regimens
  • Use of TAS-102 in the management of heavily pretreated metastatic gastric/GEJ cancer
  • Principal outcomes in the Phase III KEYNOTE-811 trial evaluating first-line pembrolizumab/trastuzumab/chemotherapy for metastatic HER2-positive gastric/GEJ adenocarcinoma
  • DESTINY-Gastric trials of T-DXd for progressive HER2-positive gastric/GEJ cancer
  • Key findings from the Phase II FIGHT trial of first-line bemarituzumab/chemotherapy for FGFR2b-positive metastatic gastric/GEJ cancer
  • Key data with first-line atezolizumab/bevacizumab for unresectable hepatocellular carcinoma (HCC)
  • Roles of sorafenib and lenvatinib as first-line therapy for unresectable HCC
  • Results from the Phase III COSMIC-312 study evaluating first-line cabozantinib/atezolizumab versus sorafenib for metastatic HCC
  • Emerging results from the Phase III HIMALAYA trial evaluating durvalumab/tremelimumab for unresectable HCC
  • Long-term outcomes with anti-angiogenic agents for progressive HCC
  • Results from the TOPAZ-1 trial of first-line durvalumab/chemotherapy for advanced biliary tract cancers
  • FDA approvals of pemigatinib and infigratinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
  • Results with futibatinib for intrahepatic cholangiocarcinoma with FGFR2 mutation from the FOENIX-CCA2 trial
  • Ivosidenib for previously treated cholangiocarcinoma with an IDH1 mutation
  • Available data with liposomal irinotecan (nal-IRI) combined with 5-FU/leucovorin for progressive metastatic biliary tract cancer
  • Immune checkpoint inhibitors in combination with other systemic therapies for biliary tract cancer
  • Preoperative chemotherapy with and without radiation therapy for resectable or borderline-resectable pancreatic adenocarcinoma (PAD)
  • Selection of adjuvant systemic therapy for patients with resected PAD
  • Optimal selection of first- and later-line treatment for patients with metastatic PAD
  • First-line nal-IRI, 5-FU/leucovorin and oxaliplatin (NALIRIFOX) for metastatic PAD
  • Patient selection for and practical integration of nal-IRI for relapsed metastatic PAD
  • BRCA1/2 mutations and other DNA damage-response abnormalities in PAD
  • Key efficacy and safety findings with and optimal integration of olaparib as maintenance therapy after first-line chemotherapy for metastatic PAD
  • PARP inhibitors combined with other anticancer therapies for metastatic PAD

Lung Cancer | 2:40 PM – 3:45 PM

  • FDA approval of adjuvant osimertinib; patient selection and optimal incorporation into clinical care
  • Optimal first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with EGFR tumor mutations
  • Available data with and ongoing evaluation of the novel HER3-directed antibody-drug conjugate patritumab deruxtecan for metastatic EGFR tyrosine kinase inhibitor-resistant NSCLC
  • Key data informing the FDA approvals of mobocertinib and amivantamab for patients with EGFR exon 20 insertion mutations who have experienced disease progression on first-line chemotherapy
  • Alectinib, brigatinib or lorlatinib as first-line therapy for patients with NSCLC and ALK rearrangements
  • Principal efficacy and safety results with entrectinib for NSCLC with a ROS1 rearrangement; appropriate integration into clinical practice
  • Published data with and ongoing trials of other “next-generation” ROS1 inhibitors (eg, repotrectinib, larotrectinib, lorlatinib, ceritinib)
  • Available data with selpercatinib and with pralsetinib for patients with advanced NSCLC and RET alterations; optimal integration into clinical practice
  • Current clinical roles of capmatinib and tepotinib for NSCLC with a MET exon 14 mutation
  • Principal efficacy and safety findings with sotorasib for pretreated NSCLC with a KRAS G12C-mutation in the Phase II CodeBreaK 100 trial and integration of this agent into routine practice
  • Key outcomes from the Phase II DESTINY-Lung01 study leading to the FDA breakthrough therapy designation of trastuzumab deruxtecan for NSCLC with HER2 mutation
  • Results from the Phase III CheckMate 816 trial evaluating neoadjuvant nivolumab in combination with chemotherapy for resectable NSCLC
  • FDA approval and current clinical role of adjuvant atezolizumab; principal findings from the Phase III IMpower010 trial evaluating atezolizumab after adjuvant chemotherapy for patients with completely resected NSCLC
  • Long-term data from the Phase III PACIFIC trial of consolidation durvalumab after chemoradiation therapy for unresectable Stage III NSCLC
  • Other ongoing and planned clinical trials of immune checkpoint inhibitors for patients with nonmetastatic NSCLC
  • Clinical trial database supporting the FDA approvals of pembrolizumab and atezolizumab as monotherapy and combined with chemotherapy as first-line treatment
  • Available efficacy and safety data from the Phase III EMPOWER-Lung 1 trial of first-line cemiplimab monotherapy for patients with NSCLC positive for PD-L1 in ≥50% of tumor cells; FDA approval and current clinical role
  • Results from the Phase III EMPOWER-Lung 3 study demonstrating an overall survival advantage with cemiplimab in combination with platinum-based chemotherapy as first-line therapy for NSCLC
  • Phase III clinical trial results (CheckMate 227, CheckMate 9LA) with first-line nivolumab/ipilimumab with and without chemotherapy; patient selection and optimal integration into practice
  • POSEIDON: A Phase III trial evaluating durvalumab or durvalumab/tremelimumab in combination with platinum-based chemotherapy versus chemotherapy alone as first-line therapy
  • Efficacy and safety observed with the anti-TIGIT monoclonal antibody tiragolumab in combination with atezolizumab in patients with PD-L1-positive metastatic NSCLC
  • Ongoing investigation of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan for patients with progressive metastatic NSCLC
  • Key efficacy and safety findings with chemotherapy in combination with atezolizumab or durvalumab for previously untreated extensive-stage small cell lung cancer (SCLC)
  • Available data with and current clinical role of lurbinectedin for patients with SCLC who experience disease progression after platinum-based therapy
  • FDA approval of trilaciclib and its optimal incorporation into routine practice as a means to preserve bone marrow function during chemotherapy in patients with extensive-stage SCLC

Closing Remarks | 3:45 PM – 4:00 PM

PROGRAM ADJOURNS | 4:00 PM

Target Audience
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

Learning Objectives

BREAST CANCER

  • Evaluate published research data to guide the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for patients with metastatic HER2-positive breast cancer, incorporating existing and recently approved anti-HER2 therapies.
  • Recognize common and rare side effects associated with novel anti-HER2 agents, and use this information to develop supportive management plans for patients with HER2-positive breast cancer undergoing treatment.
  • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize the use of adjuvant systemic therapy for newly diagnosed ER-positive breast cancer.
  • Consider available clinical trial findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the current roles of these agents in neoadjuvant and adjuvant treatment.
  • Individualize the selection and sequencing of systemic therapy for patients with ER-positive metastatic breast cancer, considering age, menopausal status, prior treatment course, PIK3CA mutation status, comorbidities, symptomatology and extent and sites of disease.
  • Appreciate available Phase III data documenting the efficacy of adjuvant PARP inhibition for patients with high-risk HER2-negative early breast cancer with BRCA mutations, and consider the potential role of this strategy in clinical practice.
  • Review published research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for patients with newly diagnosed high-risk localized or metastatic triple-negative breast cancer (TNBC), and use this information to make appropriate treatment recommendations.
  • Evaluate published research findings guiding the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or those who experience disease progression on front-line chemoimmunotherapy.
  • Appraise published efficacy and safety data with PARP inhibitors for patients with metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for localized and metastatic breast cancer.

LUNG CANCER

  • Evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches to neoadjuvant or adjuvant therapy for patients with nonmetastatic non-small cell lung cancer (NSCLC).
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and appropriately integrate this strategy into routine clinical practice.
  • Acknowledge the FDA approval of adjuvant EGFR tyrosine kinase inhibitor therapy for localized NSCLC with an EGFR mutation, and identify patients for whom this novel approach would be warranted.
  • Review published research documenting the safety and efficacy of EGFR tyrosine kinase inhibitors alone or in combination with other systemic approaches for metastatic NSCLC with an EGFR tumor mutation, and appropriately apply this information to patient care.
  • Assess the efficacy and safety of commercially available ALK inhibitors for patients with metastatic NSCLC with ALK rearrangements, and apply this understanding to selecting and sequencing these drugs as first- and later-line therapy.
  • Recollect other oncogenic pathways (ie, ROS1, RET, MET, HER2, KRAS) mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these targets.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy, chemobiologic therapy or anti-CTLA-4 antibodies for metastatic NSCLC, and discern how these approaches can be optimally employed in the management of this disease.
  • Develop a long-term care plan for patients with progressive NSCLC, considering exposure to prior systemic therapy, symptomatology, performance status and personal goals of treatment.
  • Appreciate available clinical trial findings informing the use of immune checkpoint inhibitors in combination with platinum-based chemotherapy for patients with previously untreated extensive-stage small cell lung cancer (SCLC).
  • Design an optimal approach to the clinical care of patients with progressive SCLC, considering the implications of prior therapeutic exposure, symptomatology and other factors.

GASTROINTESTINAL CANCERS

  • Develop a long-term care plan for patients diagnosed with colorectal cancer, considering biomarker profile, tumor location, prior exposure to systemic therapy, symptomatology, performance status (PS) and personal goals of treatment.
  • Use HER2 status, PD-L1 combined positive score and other clinical and biologic factors to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric, gastroesophageal junction or esophageal cancer.
  • Consider age, PS, liver function and other clinical factors in the selection of first- and later-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.
  • Recall clinical trial data with approved and investigational systemic interventions for localized, locally advanced or metastatic pancreatic adenocarcinoma, and establish an evidence-based approach to therapeutic selection for individual patients.
  • Apply available clinical research findings in the formation of personalized therapeutic approaches for unresectable and metastatic cancers of the biliary tract.
  • Appraise available and emerging data with investigational agents currently in clinical testing for gastrointestinal cancers, and where applicable, refer eligible patients for clinical trial participation.

GENITOURINARY CANCERS

  • Evaluate the published research database supporting the use of secondary hormonal agents in the management of nonmetastatic castration-sensitive and castration-resistant prostate cancer, and apply this information in the discussion of nonresearch treatment options for patients.
  • Explore available data with the use of cytotoxic and secondary hormonal therapy for metastatic hormone-sensitive prostate cancer to design effective treatment plans for patients.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess the available and emerging research database supporting the use of PARP inhibitors for patients with mCRPC, and discern how to optimally incorporate these agents into current and future clinical management algorithms.
  • Appreciate available Phase III data documenting the efficacy of PSMA-targeted radioligand therapy in patients with progressive PSMA-positive mCRPC, and consider the potential clinical role of this strategy.
  • Effectively apply evidence-based research and other clinical and biologic factors in the best-practice selection of first-line therapy for patients with metastatic renal cell carcinoma (RCC).
  • Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC that progresses on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other therapies.
  • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic urothelial bladder carcinoma (UBC), and determine the current utility of these agents in clinical practice.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom these approaches would be appropriate.
  • Consider available data supporting the use of anti-PD-1 antibody therapy for nonmetastatic RCC or UBC, and determine how this strategy can be appropriately integrated into patient care.
  • Reflect on available and emerging data with investigational agents and strategies currently in testing for prostate cancer, RCC and UBC, and where applicable, refer eligible patients for clinical trial participation.

CHRONIC LYMPHOCYTIC LEUKEMIA AND LYMPHOMAS

  • Individualize the selection and sequencing of systemic therapy for patients with newly diagnosed or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), considering clinical presentation, age, performance status (PS), biomarker profile and coexisting medical conditions.
  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents in the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those agents in clinical practice.
  • Consider patient age, PS and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Assess available clinical trial findings informing the use of CD19-directed CAR (chimeric antigen receptor) T-cell therapy for R/R DLBCL, MCL and FL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for CLL, FL, HL, MCL and DLBCL to support quality of life and continuation of treatment.
  • Recall new data with agents and strategies currently under investigation for CLL and various lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

MULTIPLE MYELOMA

  • Customize the selection of first-line therapy for patients with newly diagnosed multiple myeloma (MM), considering new clinical research findings and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplant.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
  • Consider published research and other clinical factors in the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory MM.
  • Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies to facilitate their integration into MM management algorithms.
  • Evaluate the biologic rationale for the use of CAR (chimeric antigen receptor) T-cell therapy directed at BCMA (B-cell maturation antigen) as a targeted therapeutic strategy for MM, and identify patients for whom this novel approach should be considered.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for MM, and counsel appropriate patients about availability and participation.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

NCPD Credit Designation Statements
This educational activity for 5 contact hours is provided by Research To Practice.

This activity is awarded 5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must return a completed Educational Assessment and Credit Form for the modules they attend. The credit form links will be emailed to participants within 5 business days of the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Research To Practice CME/NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Epizyme Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Novartis, Seagen Inc, and Taiho Oncology Inc.

The Westin Charlotte
601 South College Street
Charlotte, NC 282029
Hotel Phone: (704) 375-2600

Meeting Room
Grand Ballroom A-C (Second Floor)

North Carolina Oncology Association (NCOA) and South Carolina Oncology Society (SCOC) members, please be sure to contact the Westin Charlotte directly to book accommodations in the NCOA/SCOS room block.

Directions
The Westin Charlotte is the host hotel for the North Carolina Oncology Association (NCOA) and South Carolina Oncology Society (SCOS) Joint Conference.

 
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited and you must be registered to attend the NCOA/SCOS 2022 Joint Conference.

​ ​
Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
​ ​
STAND BY Registration other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis. We will inform you if your registration has been approved.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

​ Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

​ Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.